bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Termination of a Material Definitive Agreement
Item 1.02Termination of a Material Definitive Agreement  

On February 10, 2017, bluebird bio, Inc. (the “Company”) notified ARE-MA Region 38, LLC of its intention to terminate the lease agreement originally executed on June 29, 2015, relating to leased office space and access to a shared conference facility located at 215 First Street, Cambridge, Massachusetts (the “Lease”). In connection with the Company’s planned relocation of its corporate headquarters to new leased premises at 60 Binney Street in Cambridge, Massachusetts, termination of the Lease will be effective April 12, 2017. No termination fees are payable in connection with the termination of the Lease.

A summary of the material terms of the Lease was included in the Company’s Current Report on Form 8-K filed on July 6, 2015, which is qualified in its entirety by reference to the full text of the lease (filed as Exhibit 10.29 to the Company’s Quarterly Report on Form 10-Q filed on August 6, 2015 and incorporated herein by reference).

About bluebird bio, Inc. (NASDAQ:BLUE)

bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

bluebird bio, Inc. (NASDAQ:BLUE) Recent Trading Information

bluebird bio, Inc. (NASDAQ:BLUE) closed its last trading session up +0.75 at 76.45 with 407,284 shares trading hands.